The mechanistic/mammalian target of rapamycin (mTOR) is a serine threonine protein kinase, that belongs to the phosphatidylinositol-3-kinase-related kinase family. Molecules in this family have more than 2,500 amino acids, and they harbor a kinase domain at their C-terminals. It has been observed that the increasing prevalence of cancer along with its high healthcare cost, globally, has been driving the growth of mTOR inhibitors pipeline. For instance, the number of people living beyond cancer diagnosis reached around 14.5 million in 2014 and is expected to increase to 19 million, by 2024. In 2010, approximately $125 million was spent on cancer care in the U.S., and it is expected to reach $156 million, by 2020.
Other factors strengthening the mTOR inhibitors pipeline include smoking, obesity unhygienic food, and allergy. The study analyzed that mTOR inhibitors therapeutics pipeline comprises approximately 30 drug candidates in different stages of development.

Insights on pipeline segments

According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types.

Positive Clinical Results of mTOR Inhibitors Therapeutics Candidates

The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F. Hoffman-La-Roche AG has developed a drug candidate, ipatasertib, that acts as mTOR inhibitors. The Phase II clinical results (Study ID: NCT02162719) of the drug candidate were published in the Lancet Oncology journal. It has been observed that progression-free survival was longer in patients who received ipatasertib as compared in those who received placebo.

Most of the companies are developing innovative technologies for the synthesis or production of mTOR inhibitors. For instance, PHusis Therapeutics Inc. is using its computational modeling platform namely, PHuDock, that identify inhibitors of proteins which promotes the growth of cancer cells. Using PHuDock, X-ray structural information and surface plasmon resonance spectroscopic measurements of selected drug-like molecules, PHusis is rapidly and efficiently identifying agents involving toxicity studies, that selectively inhibit the activity of a number of these cancers driving proteins. PHuDock is applied to lead identification and optimization, as well as to predict the compounds off-target properties and toxicity, therefore delivering novel and highly effective agents with low toxicity.

These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk of toxicity, and relative to traditional approaches. Thus, these technological advancements act as a key driver for the pipeline growth.

Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.

便秘治療薬のパイプライン分析The study analyzed that the constipation therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Most of the drugs in pipeline for the treatment of constipation are in late stage of development. Constipation is a common functional gastrointestinal (GI) disorder that is most prevalent in the elderly and female population. According to the journal Clinical Interventions in Aging, published in 2015, the prevalence of the disease is around 20% in the world population, varying between 2% and 27% in different countries. The economic impact of chronic constipation is significant in the U.S., with around 100,000 constipation-related hospitalizations...

尋常性痤瘡（AV）治療薬のパイプライン分析Acne vulgaris currently exhibits a growing pipeline with approximately 49 drug candidates. Acne vulgaris epidemiology analysis forecasts an increase in the total number of prevalent cases in population aged between 10 to 45 years in the 7MM, from 166 million cases in 2016 to 178 million cases in 2023. Positive Clinical Results Supporting the Pipeline Growth Various drug candidates have shown positive clinical results and are proceeding towards further development. For instance, In May 2017, Foamix Ltd. announced that FMX101 was generally safe and well tolerated with no drug-related serious adverse events from two double-blind, randomized, placebo-controlled Phase III trials...

老視（老眼）治療薬のパイプライン分析The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms. The disease can result from the gradual decrease in the amplitude of accommodation. Insights on pipeline segments Various pharmaceutical companies such as Novartis AG, Allergan...

ニューロフィブロマトーシス（神経線維腫症）治療薬のパイプライン分析The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development. Insights on pipeline segments Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to...

男性型脱毛症（AGA）治療薬のパイプライン分析The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development. Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins. Various Technologies are Being Used for Androgenic Alopecia According to the research findings, various new technology platforms are being used by the companies for developing drug candidates to treat...

クッシング症候群治療薬のパイプライン分析Cushing’s syndrome currently exhibits a growing pipeline with 13 drug candidates, P&S Market Research Cushing’s syndrome therapeutics pipeline in 2017 The study analyzed that the Cushing’s syndrome therapeutics pipeline comprises of approximately 13 drug candidates. Insights on pipeline segments Orphan drug designations from the European Medicines Agency (EMA) is the one of the drivers for the development of pipeline drugs of Cushing’s syndrome. Majority of the pipeline drug candidates are being developed using the oral route of administration. Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing’s...

脊髄性筋萎縮症（SMA）治療薬のパイプライン分析The study analyzed that the therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. Spinal muscular atrophy is defined as the inherited genetic disease that is characterized by a failure of nerve cells called motor neurons. Motor neurons are responsible to accept the nerve impulses transmitted from the brain to the spinal cord and transmit the impulses to the muscle with the help of peripheral nerves. The loss of motor neurons leads to muscle weakness in muscles that are closest to the trunk of the body such as back, hips and shoulders. Nucleic acid therapeutics technology platform...

IL-6 阻害薬のパイプライン分析The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis. Insights on pipeline segments According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody. Positive Clinical Results of...

カンジダ症治療薬のパイプライン分析The study analyzed that the candidiasis therapeutics pipeline comprises approximately 22 drug candidates in different stages of development. Insights on pipeline segments As per the findings of the research, most of the candidiasis drug candidates are being developed to be administered by oral route. Cochleate technology platform for Candidiasis drug development Matinas Biopharma Holdings, Inc. is using Cochleate technology platform for the development of their drug candidates. The technology platform is a lipid-crystal nano-particle targeted drug delivery system, that offers a drug delivery solution with differentiating and disruptive features including oral availability, multi-organ protection, enhanced safety and targeted delivery to...

慢性閉塞性肺疾患（COPD）治療薬のパイプライン分析The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis. Insights on pipeline segments As per the findings of the research, most of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route. Human combinatorial antibody library (HuCAL) technology platform for Chronic Obstructive Pulmonary Disease drug development MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for...

単純ヘルペスウイルス（HSV）感染症治療薬のパイプライン分析The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. Insights on pipeline segments As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. New innovating technologies offer development of promising drugs Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to, Vector based technology platform, AdenoVerse technology platform, Juvari’s technology platform and Nanostat technology platform. Major companies collaborate for the development...

ぶどう膜炎治療薬のパイプライン分析The study analyzed that the uveitis therapeutics pipeline comprises 33 drug candidates in different stages of development. Uveitis is a type of inflammatory disease that causes swelling and destroys eye tissues. Occurrence of this disease can result in slight reduction of vision or lead to complete vision loss. Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, known as the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, even resulting in permanent vision loss. Durasert technology platform for Uveitis drug development pSivida Corp. is using durasert...

血友病治療薬のパイプライン分析According to a new research report “Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Hemophilia currently exhibits a strong pipeline with 53 drug candidates. Hemophilia pipeline in 2017 The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. Insights on pipeline segments The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Increasing collaboration between educational institutes, medical associations and...

心的外傷後ストレス障害（PTSD）治療薬のパイプライン分析The study analysed that the PTSD pipeline comprises of 23 drug candidates in different stages of development. PTSD is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not...

NF-kB阻害薬のパイプライン分析The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation. Insights on pipeline segments According to the research findings, most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source. Increasing prevalence of cancer...